We are seeing patients in-person and through Video Visits. Learn more about how we’re keeping you safe and please review our updated visitor policy. Please also consider supporting Weill Cornell Medicine’s efforts to support our front-line workers.
Cardiothoracic Surgery

You are here

Endobronchial Lung Volume Reduction: New Treatment Option for Patients with Severe Emphysema

What is Bronchoscopic Lung Volume Reduction?

Emphysema is a form of chronic obstructive pulmonary disease (COPD) that is characterized by destruction of air sacs (alveoli) and formation of blebs, which results in impaired gas exchange and increase in lung volume and hyperinflation.

Hyperinflation places respiratory muscles at mechanical disadvantage leading to progressive shortness of breath. Lung volume reduction aims to stop the vicious cycle of breathlessness caused by hyperinflation. 

Figure 2: Vicious cycle of breathlessness caused by hyperinflation.

Bronchoscopic lung volume reduction is a novel FDA approved procedure for patients with severe emphysema and hyperinflation. Procedure involves insertion of one way valves into most disease affected lobe, thereby allowing air to exit but not re-enter. This leads to volume reduction, improvement in symptoms and an increase in pulmonary function. Valve insertion is performed exclusively through a bronchoscope (flexible fiberoptic camera) without any need for surgical intervention. This offers additional treatment options for patients with compromised respiratory status unfit for surgery.

Proof of Efficacy

In several large clinical trials, patients treated with endobronchial lung volume reduction enjoyed improvement in lung function and quality of life compared with control group.

Contact us at 212-746-5166 to find out if bronchoscopic lung volume reduction is a right procedure for you. 

Our Surgeons

Weill Cornell Medicine Cardiothoracic Surgery 525 East 68th Street
Box 110
Suite M 404
New York, NY 10065 Directions
Phone: (212) 746-5166